Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 12/20 | 0.43 |
| ▸ | JAK1 | P23458 | 11/20 | 0.43 |
| ▸ | TYK2 | P29597 | 11/20 | 0.43 |
| ▸ | JAK3 | P52333 | 11/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21816394 | 0.83 | KDM4E (0.42) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL3458337 | 0.81 | JAK2 (0.46) | JAK2JAK1TYK2JAK3KDM4E | |
| SCHEMBL25237331 | 0.79 | JAK2 (0.38) | JAK2JAK1TYK2JAK3KDM4E | |
| SCHEMBL11300658 | 0.76 | EPHB3 (0.55) | JAK2JAK1TYK2JAK3KDM4E | |
| SCHEMBL30499933 | 0.75 | JAK2 (0.38) | JAK2JAK1TYK2JAK3TGFBR1 | |
| SCHEMBL25240695 | 0.74 | JAK2 (0.35) | JAK2JAK1TYK2JAK3KDM4E | |
| SCHEMBL25776500 | 0.74 | JAK2 (0.42) | JAK2JAK1TYK2JAK3TGFBR1 | |
| SCHEMBL31360521 | 0.71 | PARP1 (0.39) | JAK2JAK1TYK2JAK3KDM4E | |
| SCHEMBL12699179 | 0.70 | JAK2 (0.56) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL30736370 | 0.70 | SIRT3 (0.46) | JAK2KDM4EPARP1ALDH1A1TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4547669-A1 | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2025-05-07 | — | — | EP | disclosed |
| CN-119451964-A | FGFR2 and FGFR3 inhibitors and uses thereof | 英矽智能科技知识产权有限公司 | 2025-02-14 | — | — | CN | disclosed |
| WO-2024002157-A1 | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-01-04 | — | — | WO | disclosed |
| EP-3495363-B1 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 RECEPTOR ANTAGONISTIC EFFECT | SHIONOGI & CO (JP) | 2023-08-23 | — | — | EP | disclosed |
| CN-102548993-B | Cyclic (aza)indolizinecarboxamides, their preparation and their use as pharmaceuticals | SANOFI AVENTIS | 2014-12-10 | — | — | CN | disclosed |
| EP-2459557-B1 | CYCLIC (AZA)INDOLIZINECARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2013-09-18 | — | — | EP | disclosed |
| US-8415336-B2 | Cyclic (aza)indolizinecarboxamides, their preparation and their use as pharmaceuticals | SANOFI (FR) | 2013-04-09 | — | — | US | disclosed |
| US-20120232081-A1 | CYCLIC (AZA)INDOLIZINECARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2012-09-13 | — | — | US | disclosed |
| CN-102548993-A | Cyclic (aza)indolizinecarboxamides, their preparation and their use as pharmaceuticals | SANOFI AVENTIS | 2012-07-04 | — | — | CN | disclosed |
| EP-2459557-A1 | CYCLIC (AZA)INDOLIZINECARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2012-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232081-A1 | CYCLIC (AZA)INDOLIZINECARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | REN, ACE, PM20D2 | JAK2 1345/4885JAK1 1927/4885TYK2 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.